Precision BioSciences Inc
F:PBS0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Precision BioSciences Inc
F:PBS0
|
US |
|
S
|
Schloss Wachenheim AG
XMUN:SWA
|
DE |
|
A
|
ASOS PLC
OTC:ASOMF
|
UK |
|
S
|
Sberbank Rossii PAO
F:SBNC
|
RU |
|
China State Construction International Holdings Ltd
OTC:CCOHF
|
HK |
|
F
|
Fulton Financial Corp
F:FU5
|
US |
|
Castor Maritime Inc
F:1C1A
|
CY |
|
Kingfisher PLC
F:KFI1
|
UK |
|
Capgemini SE
OTC:CGEMY
|
FR |
Balance Sheet
Balance Sheet Decomposition
Precision BioSciences Inc
Precision BioSciences Inc
Balance Sheet
Precision BioSciences Inc
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
93
|
63
|
103
|
181
|
90
|
144
|
190
|
117
|
86
|
111
|
|
| Cash Equivalents |
93
|
63
|
103
|
181
|
90
|
144
|
190
|
117
|
86
|
111
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
|
| Total Receivables |
0
|
0
|
1
|
1
|
10
|
0
|
1
|
13
|
2
|
0
|
|
| Accounts Receivables |
0
|
0
|
1
|
1
|
10
|
0
|
1
|
1
|
2
|
0
|
|
| Other Receivables |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
12
|
0
|
0
|
|
| Other Current Assets |
1
|
2
|
11
|
12
|
6
|
18
|
9
|
7
|
7
|
3
|
|
| Total Current Assets |
94
|
64
|
116
|
194
|
106
|
162
|
199
|
136
|
95
|
119
|
|
| PP&E Net |
4
|
8
|
21
|
40
|
42
|
29
|
23
|
15
|
10
|
7
|
|
| PP&E Gross |
4
|
8
|
21
|
40
|
42
|
29
|
23
|
15
|
10
|
7
|
|
| Accumulated Depreciation |
2
|
3
|
5
|
11
|
19
|
24
|
31
|
25
|
28
|
29
|
|
| Intangible Assets |
0
|
0
|
1
|
1
|
1
|
2
|
1
|
0
|
1
|
1
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
7
|
7
|
5
|
5
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
7
|
5
|
3
|
3
|
1
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
1
|
2
|
5
|
3
|
0
|
23
|
27
|
|
| Total Assets |
98
N/A
|
73
-26%
|
139
+91%
|
235
+70%
|
150
-36%
|
211
+41%
|
238
+13%
|
160
-33%
|
136
-15%
|
154
+13%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
1
|
2
|
2
|
2
|
1
|
1
|
1
|
3
|
1
|
0
|
|
| Accrued Liabilities |
1
|
1
|
3
|
8
|
11
|
13
|
12
|
8
|
9
|
8
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
22
|
0
|
0
|
|
| Other Current Liabilities |
6
|
6
|
9
|
16
|
31
|
22
|
47
|
17
|
5
|
1
|
|
| Total Current Liabilities |
8
|
9
|
14
|
27
|
43
|
36
|
60
|
50
|
15
|
9
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
2
|
22
|
0
|
22
|
22
|
|
| Other Liabilities |
95
|
90
|
85
|
70
|
63
|
82
|
96
|
91
|
43
|
31
|
|
| Total Liabilities |
103
N/A
|
99
-4%
|
99
0%
|
97
-2%
|
106
+9%
|
120
+14%
|
178
+48%
|
141
-21%
|
80
-43%
|
62
-22%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
18
|
39
|
85
|
177
|
286
|
317
|
428
|
490
|
482
|
528
|
|
| Additional Paid In Capital |
13
|
14
|
126
|
316
|
331
|
409
|
490
|
509
|
540
|
621
|
|
| Treasury Stock |
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
5
N/A
|
26
-455%
|
40
N/A
|
138
+246%
|
44
-68%
|
91
+105%
|
60
-34%
|
19
-69%
|
56
+199%
|
92
+64%
|
|
| Total Liabilities & Equity |
98
N/A
|
73
-26%
|
139
+91%
|
235
+70%
|
150
-36%
|
211
+41%
|
238
+13%
|
160
-33%
|
136
-15%
|
154
+13%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
2
|
2
|
2
|
2
|
2
|
2
|
4
|
4
|
8
|
24
|
|